23 completed. 23 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Completed 23 |
| Phase 2 | 3 | Completed 3 |
Follow Suppuration: new trials by email Literature Review of Suppuration trials Research Report on Suppuration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers LT-002-158/Placebo oral tablet(s) - Healthy Volunteer, Hidradenitis Suppurativa | Phase 1 | Completed | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | 150 | 2024-06-13 | 2026-08-27 |
| A Clinical Study With Adalimumab Biosimilar Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product] - Pharmacokinetics, Safety Issues | Phase 1 | Completed | Laboratorios Richmond S.A.C.I.F. | 150 | 2022-08-01 | 2024-03-04 |
| Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa AT193 - Hidradenitis Suppurativa | Phase 1 | Completed | Azora Therapeutics Australia Pty Ltd | 49 | 2021-11-23 | 2024-03-15 |
| A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa. RGRN-305, Placebo - Hidradenitis Suppurativa | Phase 1 | Completed | Aarhus University Hospital | 15 | 2021-09-01 | 2023-01-31 |
| Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) BDB-001 Injection, Placebo - Hidradenitis Suppurativa | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 50 | 2021-06-24 | 2024-03-26 |
| LTX-109 as Treatment for Hidradenitis Suppurativa LTX-109 gel, 3% w/w - Hidradenitis Suppurativa | Phase 1 / Phase 2 | Completed | Pharma Holdings AS | 11 | 2021-03-05 | 2021-08-30 |
| A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS) KT-474/Placebo, KT-474 - Healthy Volunteer, Atopic Dermatitis | Phase 1 | Completed | Kymera Therapeutics, Inc. | 154 | 2021-02-23 | 2022-10-24 |
| Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS 40 mg MSB11022 - Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis | Phase 1 | Completed | Fresenius Kabi SwissBioSim GmbH | 216 | 2019-07-15 | 2020-03-25 |
| Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody - Hidradenitis Suppurativa, Palmoplantar Pustulosis | Phase 1 | Completed | CSL Behring | 39 | 2019-07-04 | 2023-05-26 |
| Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections Cefadroxil, Cephalexin - Osteomyelitis, Septic Arthritis | Phase 1 | Completed | University of Colorado, Denver | 17 | 2019-05-01 | 2021-06-02 |
| Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Hydroxychloroquine - Hidradenitis Suppurativa, Hidradenitis | Phase 1 / Phase 2 | Completed | Elena Gonzalez Brant, MD | 17 | 2017-09-28 | 2020-04-02 |
| Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities Methylene Blue, 20% I.V. Fat Emulsion, Insertion of optical fiber - Abscess | Phase 1 | Completed | University of Rochester | 21 | 2014-09-01 | 2026-04-07 |
| Retapamulin Microdialysis Feasibility Study Retapamulin Microdialysis - Skin Infections, Bacterial | Phase 1 | Completed | GlaxoSmithKline | 3 | 2014-04-02 | 2017-05-15 |
| Soft Tissue Ultrasound of Infections Ultrasound - Soft Tissue Infections, Cellulitis | Phase 1 | Completed | Rhode Island Hospital | 15 | 2012-03-01 | 2015-04-29 |
| Optimization Dose Study on Pharmacokinetics and Pharmacodynamics of Colistin in Critically Ill Patients Colistin 6 million units + 240mg/8h, Colistin 6 million units + 360mg/12h - Critical Illness | Phase 1 | Completed | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 20 | 2011-10-01 | 2016-02-03 |
| Bioequivalence Study for an Isotretinoin Isotretinoin 40 mg - Skin Infections (Acne) | Phase 1 | Completed | GlaxoSmithKline | 36 | 2011-08-26 | 2017-07-18 |
| Bioequivalence Minocycline Bioequivalence Minocycline 100mg - Skin Infections (Acne) | Phase 1 | Completed | GlaxoSmithKline | 25 | 2011-06-17 | 2017-06-22 |
| A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age Ceftobiprole - Staphylococcal Skin Infections, Streptococcal Infections | Phase 1 | Completed | Basilea Pharmaceutica | 64 | 2007-08-01 | 2012-07-27 |
| A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients Ceftobiprole - Obesity, Staphylococcal Skin Infections | Phase 1 | Completed | Basilea Pharmaceutica | 25 | 2007-08-01 | 2012-08-28 |
| Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa efalizumab - Hidradenitis Suppurativa | Phase 1 | Completed | NYU Langone Health | 5 | 2005-02-01 | 2006-09-11 |
Showing 20 of 23. Sign in to see all of them.
Hidradenitis Suppurativa (11) · Cellulitis (7) · Abscess (2) · Acne Vulgaris (2) · Arthritis, Juvenile (2) · Arthritis, Psoriatic (2) · Arthritis, Rheumatoid (2) · Colitis, Ulcerative (2) · Crohn Disease (2) · Dermatitis, Atopic (2) · Encephalitis (2) · HIV Infections (2) · Infections (2) · Spondylitis, Ankylosing (2) · Staphylococcal Skin Infections (2)
Infections (21) · Skin Diseases, Infectious (18) · Skin and Connective Tissue Diseases (18) · Skin Diseases (15) · Bacterial Infections (13) · Bacterial Infections and Mycoses (13) · Skin Diseases, Bacterial (13) · Sweat Gland Diseases (11) · Hidradenitis (10) · Connective Tissue Diseases (9) · Inflammation (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Immune System Diseases (6)
Leucovorin (2) · Pyrimethamine (2) · ceftobiprole (2) · Adalimumab (1) · Azithromycin (1) · BDB001 (1) · Cefadroxil (1) · Cephalexin (1) · Granulocyte Colony-Stimulating Factor (1) · High-Energy Shock Waves (1) · Hydroxychloroquine (1) · Isotretinoin (1) · Methylene Blue (1) · Minocycline (1) · Zidovudine (1)
GlaxoSmithKline (3) · Basilea Pharmaceutica (2) · Aarhus University Hospital (1) · Azora Therapeutics Australia Pty Ltd (1) · CSL Behring (1) · Elena Gonzalez Brant, MD (1) · Fresenius Kabi SwissBioSim GmbH (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Institute of Child Health (1) · Kymera Therapeutics, Inc. (1) · Laboratorios Richmond S.A.C.I.F. (1) · Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (1) · NYU Langone Health (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Pfizer (1)
United States (10) · Australia (2) · China (2) · Denmark (2) · Argentina (1) · Germany (1) · Mexico (1) · Norway (1) · Spain (1) · United Kingdom (1)
Adam Jaffe, Dr (1) · Andrew Haynes, MD (1) · Ashwani K Sharma, MD (1) · Ashwin Gollerkeri, MD (1) · B Luft (1) · Baoxi Wang, Master (1) · Bruce Strober, MD, PhD (1) · Elena M Gonzalez Brant, MD (1) · Ethel C. Feleder, MD (1) · Laurie Christensen, BS (1) · Luft B (1)
PMID 18492739, PMID 31604104, PMID 35262901, PMID 37464107, PMID 37957373, PMID 37961683, PMID 38055242, PMID 38316055, PMID 38414658, PMID 38501946, PMID 40055981
2018 (1)